logo
Plus   Neg
Share
Email

Hikma Buys Products In Europe From Boehringer Ingelheim - Quick Facts

Hikma Pharmaceutical (HIK,HIK.L, HKMPY) announced Tuesday that it has acquired six products from Boehringer Ingelheim GmbH. The aggregate consideration is 3 million euros.

Boehringer Ingelheim is a related party of Hikma for the purposes of the UKLA Listing Rules by virtue of its 17% shareholding in Hikma.

Hikma has acquired five products in Germany, Alupent, Gastrozepin, Paracefan, Partusisten and Spiropent and one product, Mantadan, in Italy, together with inventory at closing and the supply by Boehringer Ingelheim of a stockpile of the products to cover a transition period of 20 months.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Despite opposition from the pharmaceutical industry, President Donald Trump's administration has proposed a new rule requiring companies to include the prices for prescription drug and biological products in their television advertisements. Ride-hailing company Lyft introduced a new monthly subscription plan that offers free or discounted rides for a price of $299 every 30 days. Passengers can subscribe to the monthly plan, starting today. It will be available to everyone in the U.S. by the end of the week. With an All-Access Plan, riders can get 30 rides each month worth up to $15 each. Amazon.com Inc. will continue to work with the U.S. Department of Defense or DoD despite criticism from its employees and privacy activists, the company's Founder and Chief Executive Jeff Bezos said Monday. "If big tech companies are going to turn their back on the DoD, this country is going to be in trouble," Bezos said during the Wired25 conference in San Francisco.
Follow RTT